Skip to main content
Premium Trial:

Request an Annual Quote

Even as Economy Slows, RNAi, miRNA Players Find Interested Partners in 2008

Premium
Despite the difficult economic climate, a number of RNAi and microRNA drug developers were able to secure important alliances, or even buyouts, with big pharmaceutical and biotechnology firms over the course of 2008.
 
“People continue to have strong interest in RNA as a therapeutic,” Lou Renzetti, vice president and global head of RNA therapeutics at Roche, told RNAi News earlier this month. “Those of us who have managed to make strategic investments and can ride [the financial upheaval] out … remain committed.”
 
To view a snapshot of key RNAi/miRNA partnerships forged over the past 12 months, click here.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.